What is OrSense?
OrSense is at the forefront of medical device innovation, developing and commercializing Occlusion Spectroscopy-based non-invasive monitoring technologies. These technologies are designed for the accurate measurement of hemoglobin, oxygen saturation, and other critical blood parameters. The company's proprietary SpectOLight™ technology is engineered to overcome the limitations of traditional non-invasive methods, enabling precise readings even under challenging conditions. This focus on advanced diagnostics positions OrSense as a key player in the healthcare technology sector, aiming to enhance patient monitoring and diagnostic capabilities.
How much funding has OrSense raised?
OrSense has raised a total of $26.2M across 2 funding rounds:
Private Equity
$8.2M
Unspecified
$18M
Private Equity (2001): $8.2M, investors not publicly disclosed
Unspecified (2011): $18M led by Israel Healthcare Ventures and Star Ventures
Key Investors in OrSense
Israel Healthcare Ventures
Israel HealthCare Ventures (IHCV) is a prominent Israeli venture fund with a strong focus on the life sciences sector, investing in innovative healthcare technologies and medical devices. Their strategic backing of OrSense highlights a commitment to advancing diagnostic solutions.
Star Ventures
Star Ventures is an investment entity that provides capital for companies, potentially focusing on various sectors. Their participation in OrSense's funding round suggests an interest in the medical technology and device market.
What's next for OrSense?
The recent major strategic investment signals a pivotal growth phase for OrSense. This capital infusion is expected to accelerate the company's product development pipeline, expand its market reach, and further refine its SpectOLight™ technology. With a clear trajectory supported by substantial backing, OrSense is poised to enhance its offerings in the non-invasive monitoring space, potentially leading to broader clinical adoption and improved patient outcomes. The company's strategic focus on overcoming technical hurdles in blood parameter measurement suggests a future centered on innovation and market leadership in diagnostic medical devices.
See full OrSense company page
